Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors
暂无分享,去创建一个
M. Caggana | A. Comeau | B. Therrell | M. Kharrazi | Denise M. Kay | M. Baker | S. Nasr | Rachel Lee | G. Hoffman | J. E. Hale | M. Kleyn | H. Winslow | M. C. Dorley | Ankita Sutaria | Hilary Fryman | B. Reilly | Amy D. Hietala | John D. Thompson | Charlene Sacramento | Colleen Clarke | Cheryl Harris | Holly Richards
[1] K. Southern,et al. Cystic fibrosis newborn screening: the importance of bloodspot sample quality , 2020, Archives of Disease in Childhood.
[2] D. Peroni,et al. Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy , 2020, Diagnostics.
[3] Todd W. Allen,et al. Galactose-1-phosphate uridyltransferase dried blood spot quality control materials for newborn screening tests. , 2015, Clinical biochemistry.
[4] R. Iles,et al. Thirty-years of screening for cystic fibrosis in East Anglia , 2012, Archives of Disease in Childhood.
[5] P. Farrell,et al. Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: challenges in newborn dried blood spot screening. , 2012, Molecular genetics and metabolism.
[6] P. Farrell,et al. Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening , 2011, Pediatric pulmonology.
[7] B. Adam,et al. The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States. , 2011, Clinical biochemistry.
[8] P. Farrell,et al. Clarification of Laboratory and Clinical Variables That Influence Cystic Fibrosis Newborn Screening With Initial Analysis of Immunoreactive Trypsinogen , 2009, Pediatrics.
[9] G. Cutting,et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. , 2008, The Journal of pediatrics.
[10] A. Clark,et al. Cystic Fibrosis Diagnosed After 2 Months of Age Leads to Worse Outcomes and Requires More Therapy , 2007, Pediatrics.
[11] M. Corey,et al. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. , 2006, The Journal of pediatrics.
[12] R. Laessig,et al. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. , 2005, The Journal of pediatrics.
[13] J. Zieleński,et al. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. , 2005, The Journal of pediatrics.
[14] R. Parad,et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. , 2004, Pediatrics.
[15] T J David,et al. Newborn Screening for Cystic Fibrosis , 2004, Journal of the Royal Society of Medicine.
[16] M. Kosorok,et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. , 1997, Pediatrics.
[17] Lee-Jen Wei,et al. Newborn Screening for Cystic Fibrosis Is Complicated by Age-Related Decline in Immunoreactive Trypsinogen Levels , 1990, Pediatrics.
[18] M. Seia,et al. Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates. , 2012, JIMD reports.
[19] C. Castellani,et al. A survey of newborn screening for cystic fibrosis in Europe. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.